McKay P J, Murphy J A, Cameron S, Burnett A K, Campbell M, Tansey P, Franklin I M
Bone Marrow Transplant Unit, Royal Infirmary, Glasgow, UK.
Bone Marrow Transplant. 1996 Jan;17(1):63-6.
Patients who require a bone marrow transplant (BMT) for leukaemia, lymphoma or other haematological disorders receive large quantities of blood products, including red cell concentrates, during the transplant period. Many receive red cell transfusions as part of treatment prior to BMT, adding to the potential iron load. However, organ dysfunction as a consequence of the transfused iron load would be surprising given the amounts of iron transfused. We studied 76 survivors of allogeneic and autologous BMT who were at least 1 year post-transplant and found that the majority (88%) had raised ferritins. Impaired liver function was common in these patients and in half was unexplained by viral hepatitis, veno-occlusive disease or graft-versus-host disease (GVHD), suggesting that iron overload may be an important contributing factor to liver disease in the stable post-transplant setting. This view is supported by the observation of improving liver function tests in 10 patients after a trial of venesection therapy.
因白血病、淋巴瘤或其他血液系统疾病而需要进行骨髓移植(BMT)的患者,在移植期间会接受大量血液制品,包括红细胞浓缩液。许多患者在BMT之前作为治疗的一部分接受红细胞输血,这增加了潜在的铁负荷。然而,鉴于所输注的铁量,因输血铁负荷导致器官功能障碍是令人惊讶的。我们研究了76例同种异体和自体BMT的幸存者,他们在移植后至少1年,发现大多数(88%)铁蛋白升高。这些患者中肝功能受损很常见,其中一半无法用病毒性肝炎、静脉闭塞性疾病或移植物抗宿主病(GVHD)来解释,这表明铁过载可能是移植后稳定期肝病的一个重要促成因素。对10例患者进行放血疗法试验后肝功能检查改善的观察结果支持了这一观点。